| 1521/2347 | US=67 / Biol/Mol Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR |
| 1522/2347 | US=67 / Biol/Mol Atieh DM, Vahdat LT. Targeted therapy for beast cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 309-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE MAMA; TERAPIA-ALVO; TRASTUZUMABE; HER-2; MICROARRAY; BEVACIZUMABE; VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; LAPATINIBE; ANTICORPOS MONOCLONAIS; INIBIDOR DA TIROSINA QUINASE |
| 1523/2347 | US=67 / Biol/Mol Gupta A, Kirkwood JM. Melanoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 343-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MELANOMA; PATOGENESE MOLECULAR; TERAPIA ALVO; INTERFERON; STAT; ANTISENSE BC12; BRAF; APOPTOSE; CICLO CELULAR |
| 1524/2347 | US=67 / Biol/Mol Borghaei H, Binyamin L, Astsaturov I, Weiner LM. Antibody therapy of cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 371-412. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; ANTICORPOS MONOCLONAIS; TERAPIA DE ANTICORPOS; CITOTOXICIDADE CELULAR DEPENDENTE DE ANTICORPO; CITOTOXICIDADE DEPENDENTE DE COMPLEMENTO; IMUNOCONJUGADOS |
| 1525/2347 | US=67 / Biol/Mol Vogl DT, Gewirtz AM. Nucleic acid therapies for cancer treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 413-29. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; ACIDO NUCLEICO; OLIGONUCLEOTIDEOS ANTISENSE; DNA; RNAI |
| 1526/2347 | US=67 / Biol/Mol Nakamura T, Russell SJ. Engineering oncolytic measles viruses for targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 431-45. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. VIRUS ONCOLITICOS; SARAMPO; TERAPIA DE CANCER; TERAPIA-ALVO; VIROTERAPIA |
| 1527/2347 | US=67 / Biol/Mol Perales MA, Wolchok JD, Kaufman HL. Vaccines as targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 447-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 1528/2347 | US=67 / Biol/Mol Koon HB, Atkins MB. Cytokine-based therapy for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 471-507. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; CITOQUINA; INTERFERON; INTERLEUCINA; IMUNOTERAPIA; RESISTENCIA; LEUCEMIA DE CELULAS PILOSAS; LEUCEMIA MIELOIDE CRONICA; LINFOMA NAO-HODGKIN; MELANOMA; CARCINOMA DE CELULAS RENAIS; SARCOMA DE KAPOSI |
| 1529/2347 | US=67 / Biol/Mol Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE |
| 1530/2347 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 1531/2347 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 1532/2347 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |
| 1533/2347 | US=67 / Biol/Mol Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin analogue therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 585-637. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. TERAPIA ANALOGA DA SOMATOSTATINA; ACROMEGALIA; CARCINOIDE; SINDROME CARCINOIDE; HORMONIO DE CRESCIMENTO; LUTECIO; OCTREOTIDE; NEUROENDOCRINO; PROLIFERACAO; CINTILOGRAFIA; RECEPTOR DE SOMATOSTATINA; SOMATULINA; TUMOR; ITRIO |
| 1534/2347 | US=67 / Biol/Mol Dy GK, Adjei AA. Patient selection for rational development of novel anticancer agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 641-8. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. AGENTES ANTICANCERIGENOS; SELECAO DOS PACIENTES; TERAPIA-ALVO; BIOMARCADORES; EXPRESSAO GENICA; AMPLIFICACAO GENICA |
| 1535/2347 | US=67 / Biol/Mol Dubey S, Schiller JH. Clinical trial design with targeted agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 649-55. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ESTUDO CLINICO; AGENTES DIRECIONADOS; ENSAIOS CLINICOS; AGENTES ALVOS |
| 1536/2347 | US=67 / Biol/Mol Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO |
| 1537/2347 | US=67 / Biol/Mol Shankar LK, Menkens A, Sullivan DC. Molecular imaging in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 675-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; IMAGEM MOLECULAR; BIOMARCADORES DE IMAGEM; BIOMARCADORES IN VIVO; TESTES DE CANCER; PROCESSO NEOPLASICO; AGENTES PET; CONTRASTE AGENTES MR; TECNOLOGIA OPTICA |
| 1538/2347 | US=67 / Biol/Mol Chen HX, Dancey JE. Combinations of molecular-targeted therapies: opportunities and challenges. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 693-705. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 1539/2347 | US=67 / Biol/Mol Tomaszewski JE, Doroshow JH. Preclinical development of molecularly targeted agents in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; DESENVOLVIMENTO PRE-CLINICO; AGENTES ALVO MOLECULARES; AGENTES ANTITUMORAIS; DESENVOLVIMENTO DE DROGAS; ALVOS MOLECULARES; FARMACOCINETICA; FARMACODINAMICA; TOXICOLOGIA |
| 1540/2347 | US=80 / Biol/Mol Li D, Hackett J, Chan M, Pennello G, Gutman S. Regulatory issues in the co-development of oncology drugs and proteomic tests: an overview. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 237-58. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. |